Trials / Completed
CompletedNCT02451943
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 509 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaratumab | Administered IV |
| DRUG | Doxorubicin | Administered IV |
| DRUG | Placebo | Administered IV |
Timeline
- Start date
- 2015-09-14
- Primary completion
- 2018-12-05
- Completion
- 2024-06-27
- First posted
- 2015-05-22
- Last updated
- 2025-07-15
- Results posted
- 2019-12-17
Locations
114 sites across 25 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Poland, Russia, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02451943. Inclusion in this directory is not an endorsement.